

## Overview

### Useful For

Molecular confirmation of clinically suspected Friedreich ataxia

### Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
CULFB	Fibroblast Culture for Genetic Test	Yes	No
CULAF	Amniotic Fluid Culture/Genetic Test	Yes	No
MATCC	Maternal Cell Contamination, B	Yes	No
_STR1	Comp Analysis using STR (Bill only)	No, (Bill only)	No
_STR2	Add'l comp analysis w/STR (Bill Only)	No, (Bill only)	No

### Genetics Test Information

This test assesses for GAA (trinucleotide repeat expansions within the *FXN* gene to confirm a molecular diagnosis of Friedreich ataxia.

### Testing Algorithm

**For prenatal specimens only:** If amniotic fluid (nonconfluent cultured cells) is received, the amniotic fluid culture will be added at an additional charge.

If chorionic villus specimen (nonconfluent cultured cells) is received, the fibroblast culture will be added at an additional charge.

For any prenatal specimen that is received, maternal cell contamination studies will be added.

### Special Instructions

- [Informed Consent for Genetic Testing](#)
- [Molecular Genetics: Neurology Patient Information](#)
- [Blood Spot Collection Card-Spanish Instructions](#)
- [Blood Spot Collection Card-Chinese Instructions](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)
- [Blood Spot Collection Instructions](#)

### Method Name

---

Polymerase Chain Reaction (PCR)

**NY State Available**

Yes

**Specimen****Specimen Type**

Varies

**Shipping Instructions**

Specimen preferred to arrive within 96 hours of collection.

**Specimen Required**

**Patient Preparation:** A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

**Submit only 1 of the following specimens:**

**Specimen Type:** Whole blood

**Container/Tube:**

**Preferred:** Lavender top (EDTA) or yellow top (ACD)

**Acceptable:** Any anticoagulant

**Specimen Volume:** 3 mL

**Collection Instructions:**

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**

**Specimen Stability Information:** Ambient (preferred)/Refrigerated

**Due to its complexity, prenatal testing will not be accepted without approval from the laboratory. Call 800-533-1710 for prenatal testing consultation.** Prenatal specimens can be sent Monday through Thursday and **must be received by 5 p.m. CST on Friday** in order to be processed appropriately. All prenatal specimens must be accompanied by a maternal blood specimen. Order MATCC / Maternal Cell Contamination, Molecular Analysis, Varies on the maternal specimen.

**Specimen Type:** Amniotic fluid

**Container/Tube:** Amniotic fluid container

**Specimen Volume:** 20 mL

**Specimen Stability Information:** Refrigerated (preferred)/Ambient

**Specimen Type:** Chorionic villi

**Container/Tube:** 15-mL tube containing 15 mL of transport media

---

**Specimen Volume:** 20 mg

**Specimen Stability Information:** Refrigerated

**Acceptable:**

**Specimen Type:** Confluent cultured cells

**Container/Tube:** T-25 flask

**Specimen Volume:** 2 Flasks

**Collection Instructions:** Submit confluent cultured cells from another laboratory.

**Specimen Stability Information:** Ambient (preferred)/Refrigerated

**Specimen Type:** Blood spot

**Supplies:** Card-Blood Spot Collection (Filter Paper) (T493)

**Container/Tube:**

**Preferred:** Collection card (Whatman Protein Saver 903 Paper)

**Acceptable:** Perkin/Elmer 266 (formerly Ahlstrom 226) filter paper, or Blood Spot Collection Card

**Specimen Volume:** 5 Blood spots

**Collection Instructions:**

1. An alternative blood collection option for a patient older than 1 year of age is a fingerstick. See [Dried Blood Spot Collection Tutorial](#) for how to collect blood spots via fingerstick.
2. Let blood dry on the filter paper at ambient temperature in a horizontal position for a minimum of 3 hours.
3. Do not expose specimen to heat or direct sunlight.
4. Do not stack wet specimens.
5. Keep specimen dry.

**Specimen Stability Information:** Ambient (preferred)/Refrigerated

**Additional Information:**

1. For collection instructions, see [Blood Spot Collection Instructions](#)
2. For collection instructions in Spanish, see [Blood Spot Collection Card-Spanish Instructions](#) (T777)
3. For collection instructions in Chinese, see [Blood Spot Collection Card-Chinese Instructions](#) (T800)
4. Due to lower concentration of DNA yielded from blood spots, it is possible that additional specimen may be required to complete testing.

**Forms**

**1. New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:

-[Informed Consent for Genetic Testing](#) (T576)

-[Informed Consent for Genetic Testing-Spanish](#) (T826)

2. [Molecular Genetics: Neurology Patient Information](#)

**Specimen Minimum Volume**

Amniotic fluid: 10 mL

Blood: 0.5 mL

Chorionic villi: 5 mg

Blood spots: 5 punches, 3-mm diameter

## Reject Due To

Specimens will be evaluated at Mayo Clinic Laboratories for test suitability

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies (preferred)	0 hours	

## Clinical & Interpretive

### Clinical Information

Friedreich ataxia (FA) is one of the most commonly inherited ataxias and is characterized by progressive gait and limb ataxia, dysarthria, dysphagia, and sensory loss. The phenotypic spectrum includes nonneurologic manifestations, particularly cardiomyopathy and diabetes mellitus. Onset typically occurs between the ages of 10 to 16 years; however, late-onset and early-onset variants have been reported. FA is autosomal recessively inherited. The majority of affected individuals (96%) have homozygous GAA trinucleotide repeat expansions in intron 1 of *FXN*. The remaining affected individuals have a heterozygous GAA trinucleotide repeat expansion and another pathogenic *FXN* variant detectable by sequencing or deletion and duplication analysis. Correlation exists between the size of the GAA repeat and disease onset and severity, with larger alleles associated with earlier onset and more severe disease presentation. GAA expansions may demonstrate instability during meiosis and mitosis. The GAA repeat size may expand or contract during transmission to offspring and GAA repeat size may vary in different tissues. The GAA trinucleotide repeat is polymorphic in the general population, with the number of nondisease-associated repeats ranging from 5 to 33. Repeats of 66, or greater, are fully penetrant disease-associated alleles; however, the majority of affected individuals have repeat sizes in the 600 to 1200 repeat range. Repeat sizes of 34 to 65 fall within a borderline range. Borderline alleles are of unclear significance and may be associated with clinical symptoms of FA and/or a risk for expansion to a full penetrance allele when transmitted to offspring.

### Reference Values

*FXN*

[Normal alleles: <34 GAA repeats](#)

Borderline alleles: 34-65 GAA repeats

Expanded alleles: >65 GAA repeats

An interpretive report will be provided.

### Interpretation

An interpretive report will be provided.

### Cautions

For familial testing, it is important to first document the molecular etiology of disease in an affected family member to confirm that a repeat expansion is the underlying mechanism of disease in the family. Specifically, this assay will not detect nonrepeat expansion variants (eg, sequence variants, deletions, and duplications).

---

It is strongly recommended that patients undergoing genetic testing receive genetic counseling.

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data, such as frataxin concentrations (see FFRWB / Friedreich Ataxia, Frataxin, Quantitative, Blood and FFRBS / Friedreich Ataxia, Frataxin, Quantitative, Blood Spot). Errors in test interpretation may occur if the provided information is inaccurate or incomplete.

Rare variants (ie, polymorphisms) may exist, such as intron 1 deletions, which could lead to false-negative results. If GAA-repeat expansion results do not match clinical findings, additional testing should be considered.

Due to somatic mosaicism, GAA repeat-sizes in peripheral blood specimens may not reflect GAA repeat-sizes in other tissues (eg, central nervous system).

Bone marrow transplants from allogenic donors will interfere with testing. Call Mayo Clinic Laboratories at 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

### Clinical Reference

1. Campuzano V, Montermini L, Molto MD, et al: Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. *Science*. 1996 Mar 8;271(5254):1423-1427
2. Delatycki MB, Bidichandani SI: Friedreich ataxia-pathogenesis and implications for therapies. *Neurobiol Dis*. 2019 Dec;132:104606
3. Corben LA, Lynch D, Pandolfo M, Schulz JB, Delatycki MB, Clinical Management Guidelines Writing Group: Consensus clinical management guidelines for Friedreich ataxia. *Orphanet J Rare Dis*. 2014 Nov 30;9:184
4. Sharma R, De Biase I, Gomez M, Delatycki MB, Ashizawa T, Bidichandani SI: Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. *Ann Neurol*. 2004 Dec;56(6):898-901
5. Montermini L, Richter A, Morgan K, et al: Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. *Ann Neurol*. 1997 May;41(5):675-682

### Performance

#### Method Description

A polymerase chain reaction-based assay is used to amplify across the region of *FXN* containing GAA repeats.(Unpublished Mayo method)

#### PDF Report

No

#### Day(s) Performed

Monday, Wednesday

#### Report Available

14 to 21 days

### Specimen Retention Time

Whole blood: 2 weeks (if available); Extracted DNA: 3 months

### Performing Laboratory Location

Rochester

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

### CPT Code Information

81284

81265-Maternal Cell Contamination (if appropriate)

88233-Fibroblast Culture (if appropriate)

88235-Amniotic Fluid Culture (if appropriate)

88240-Cryopreservation (if appropriate)

### LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
AFXN	FXN, Repeat Expansion Analysis	21762-0

Result ID	Test Result Name	Result LOINC® Value
609752	Result Summary	50397-9
609753	Result	21762-0
609754	Interpretation	69047-9
609755	Reason for Referral	42349-1
609756	Specimen	31208-2
609757	Source	31208-2
609758	Method	85069-3
609759	Disclaimer	62364-5
609760	Released By	18771-6